Blog
Clinical Connection
Thought leadership on the clinical impact on workers' compensation and auto no-fault.
Brand–Generic Pipeline Q1 2023
The following list represents a summary of new medications approved by the U.S. Food and Drug Administration (FDA), and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. Off-label use for the treatment of conditions outside of FDA-approved indications may not be supported by medical treatment guidelines or Optum Workers’ Compensation and Auto No-Fault.
New medications
There were no new medications relevant to workers’ compensation and/or auto injuries launched during this quarter.
First-time generics or brand alternatives
For more information about these medications, click on the link in the brand-name medication to visit the manufacturer’s website.
| Generic name | Brand name | Strength(s) and dosage form(s) | Use/indication* | Launch date |
|---|---|---|---|---|
| Diclofenac potassium | Cambia® | 50 mg oral solution | Acute treatment of migraine | 1/04/2023 |
| Topiramate | Trokendi XR® | 25 mg, 50 mg, 100 mg extended-release capsules† |
Preventive treatment of migraine; various seizures | 1/04/2023 |
| Lurisadone | Latuda® | 20 mg, 40 mg, 60 mg, 80 mg and 120 mg tablets |
Schizophrenia; major depressive episode associated with bipolar I disorder | 2/20/2023 |
| Fluticasone/salmeterol | Advair HFA® | 45 mcg/21 mcg, 115 mcg/21 mcg, and 230 mcg/21 mcg per actuation |
Asthma | 3/01/2023 |
*This list is focused on medications related to workers’ compensation and/or auto injuries and may not include all medications made available this quarter
†200 mg XR strength is not available in generic
If you have any questions, please contact your account manager, clinical liaison, or our Clinical Services team at 1-877-275-7674 ext. 8612.
